Emcure Pharmaceuticals Ltd

BSE Code : 544210
NSE Symbol : EMCURE
ISIN : INE168P01015
Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

Trade Now

Get Quotes

1,327.40 -5.00(-0.38%)

Open Price (₹)

1,332.40

Prev. Close (₹)

1,332.40

Volume (No’s)

79,144

Market Cap (₹)

25,152.02

Low Price (₹)

1,318.30

High Price (₹)

1,364.00

Chart

Technical Chart

Corparate Information

Financials

Corporate Action

Board Meetings

Start Date	End Date	Purpose
13-May-2025	22-May-2025	Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Audited financial results (standalone and consolidated) for the quarter and year ended March 31 2025 and recommendation of Final Dividend if any. Board of Directors of the Company at its meeting held today i.e. Thursday, May 22, 2025, has inter-alia transacted and approved/ recommended the following businesses: Recommended a final dividend of Rs. 3 / - (Rupees Three only) per equity share of Rs. 10 /- (Rupees Ten only) each of the Company (at the rate of 30%) for the financial year ended March 31, 2025, subject to approval of the Members of the Company at the ensuing Annual General Meeting of the Company. Dividend, once approved by the Members, shall be paid within the prescribed timeline under the Companies Act, 2013. Outcome of Board Meeting held on May 22, 2025: 1. Audited Financial Results (standalone and consolidated) for the quarter and year ended March 31, 2025. 2. Dividend 3. Re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company 4. Appointment of Secretarial Auditors of the Company 5. Incorporation of a wholly-owned Subsidiary by the name 'Emcure Generics Private Limited' in Pune, Maharashtra, India Read less.. Intimation of proposed incorporation of a Wholly-owned Subsidiary by the name 'Emcure Generics Private Limited' Re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company. (As Per BSE Announcement Dated on 22.05.2025)
24-Jan-2025	06-Feb-2025	Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31 2024. The trading window for dealing in securities of the Company by the Designated Persons and their relatives has been already closed from January 01 2025 as communicated earlier vide our letter No. EPL/CS/SE/0033/2024 dated December 18 2024 and shall remain closed till 48 hours after the declaration of the financial results i.e. till February 08 2025 in terms of the Companys Code of Conduct for regulating monitoring and reporting of insider trading in the securities of the Company framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended. Unaudited Financial Results (Consolidated & Standalone) For the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 06/02/2025)
29-Oct-2024	07-Nov-2024	Quarterly Results Outcome of Board Meeting held on November 7, 2024 (As per BSE Announcement Dated on 07/11/2024)
06-Aug-2024	13-Aug-2024	Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30 2024. The Board of Directors of the Company at its meeting held today i.e. Tuesday, August 13, 2024 has inter-alia approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, as reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the Listing Regulations, we are enclosing herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid Results as issued by B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, is also enclosed herewith as Annexure B. (As Per Bse Announcement Dated on 13.08.2024)